


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-10.91%
+9.98%
-2.35%
-4.15%
+9.30%
KTTA
Pasithea Therapeutics Cor
$1.12
KTTA Price Performance
$0.72 (+55.56%)
$0.72 (+55.56%)
$0.72 (+55.56%)
$2.79 (-59.86%)
KTTA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Price under $5

High volatilty

KTTA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future
![]()
KTTA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
KTTA Street Sentiment is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is KTTA current stock price?
What are KTTA stock strengths?
What is KTTA Risk Level?
What is KTTA market cap and volume?
What is KTTA current Stock IQ?
Should I buy KTTA stock right now?
Is KTTA a Strong Buy right now?
What does a 'Strong Buy' rating mean for KTTA?
What does a 'Strong Sell' rating mean for KTTA?
What factors influence KTTA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-10.91%
+9.98%
-2.35%
-4.15%
+9.30%
KTTA
Pasithea Therapeutics Cor
Current Price
$1.12

KTTA Price Performance
$0.72 (+55.56%)
$0.72 (+55.56%)
$0.72 (+55.56%)
$2.79 (-59.86%)
KTTA Analysts Opinion
KTTA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future
![]()
KTTA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
KTTA Street Sentiment is extremely bullish and have negative views on the near-term outlook
KTTA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Price under $5

High volatilty

Average key support and resistance price levels
KTTA Stock IQ
KTTA Latest Analysis
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock. Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors including Vivo Capital Janus Henderson Investors Coastlands Capital Columbia Threadneedle Investments Adage Capital Partners and Squadron Capital Management KTTAW)) a clinical-stage biotechnology company developing PAS-004 a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type
Tue Dec 2, 2025
Pasithea Prices $60 Mln Offering To Advance PAS-004 And Broader Pipeline . (RTTNews) - Shares of Pasithea Therapeutics Corp. (KTTA) rose up to 38% after the company announced it has priced a $60 million public offering of 80 million shares of common stock at $0.75 per share.
Mon Dec 1, 2025
Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise . (RTTNews) - Pasithea Therapeutics Corp. (KTTA) gained 38.68% rising $0.41 to $1.47 after the company announced it priced a $60 million public offering issuing 80 million shares (or equivalent pre-funded warrants) at $0.75 per share.
Fri Nov 28, 2025
Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor Stock Up . (RTTNews) - Pasithea Therapeutics Corp. (KTTA) announced on Friday that it has set a price for a public offering of 80 million shares at $0.75 each which should bring in around $60 million to help fund the development of their main product PAS-004.
Fri Nov 28, 2025
Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today. KTTA) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate PAS-004 capped by a new $1 million grant from the .KTTA is among today’.s top performers. Investors are reacting to a three-day run of news around PAS-004. On Monday Pasithea reported completion of Cohort 7 in its ongoing Phase 1 ...
Wed Nov 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
KTTA Stock trends
KTTA Stock performance
KTTA Stock analysis
KTTA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.